Anthrax cost-effectiveness of therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
Joao Silva (talk | contribs) |
||
| Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
Given the morbidity and mortality associated with Anthrax infection, and the low cost of safe and effective antibiotics, current pharmacotherapy to treat anthrax is relatively cost-effective. | Given the [[morbidity]] and [[mortality]] associated with Anthrax infection, and the low cost of safe and effective [[antibiotics]], current [[pharmacotherapy]] to treat anthrax is relatively cost-effective. | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Revision as of 00:40, 18 July 2014
|
Anthrax Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Anthrax cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Anthrax cost-effectiveness of therapy |
|
Risk calculators and risk factors for Anthrax cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Given the morbidity and mortality associated with Anthrax infection, and the low cost of safe and effective antibiotics, current pharmacotherapy to treat anthrax is relatively cost-effective.